GlassScriptPhysician profile
Rafael Cavalcanti
NPI 1417248089
$18,887.79
in general payments reported to CMS, 2019-2025
27 companies · $5,734 in 2025
The $5,734 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,595 · 2020: $1,301 · 2021: $2,060 · 2022: $1,750 · 2023: $2,045 · 2024: $1,402 · 2025: $5,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,259 · Travel and Lodging: $2,422 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,259.49 |
| Travel and Lodging | $2,421.59 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,206.04 | 2019-2025 | Watchman Access System, Farapulse, Watchman |
| Medtronic Vascular, INC. | $3,085.37 | 2019-2020 | |
| Abbott Laboratories | $1,927.27 | 2019-2025 | Aveir, Ensite Precision, Ensite |
| Medtronic, INC. | $1,926.36 | 2021-2025 | Evera Mri Xt Dr Surescan, Micra, Pulseselect |
| Altathera Pharmaceuticals LLC | $1,865.49 | 2025 | Sotalol Hydrochloride |
| Biosense Webster, INC. | $1,360.39 | 2019-2025 | Carto 3, Nuvision Ice Catheter, Smartablatetm System Rf Generator |
| Novartis Pharmaceuticals Corporation | $902.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $594.04 | 2019-2025 | Camzyos, Eliquis |
| Cardiva Medical, INC. | $581.82 | 2021-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire, Savvywire |
| Astrazeneca Pharmaceuticals LP | $524.90 | 2019-2023 | Lokelma |
| Amgen INC. | $518.06 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $412.45 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $283.98 | 2019-2024 | Lifevest |
| Atricure, INC. | $282.13 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.47 | 2020-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $221.00 | 2020-2024 | Selectra, Amvia Edge, Renamic Neo |
| Vital Connect, INC | $218.90 | 2023-2025 | Vitalpatch Rtm |
| Philips North America LLC | $189.21 | 2024 | (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $151.71 | 2021 | |
| Novo Nordisk INC | $96.62 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abiomed | $87.22 | 2023 | Impella |
| Pfizer INC. | $80.34 | 2020-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $30.54 | 2023 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $24.00 | 2023 | Artis Zee Multi-Purpose |
| Angiodynamics, INC. | $18.06 | 2020 | |
| Convatec INC. | $17.88 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Cavalcanti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.